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Starting from the early descriptions of Kraepelin and 
Bleuler, the construct of schizotypy was developed from 
observations of aberrations in nonpsychotic family mem-
bers of schizophrenia patients. In contemporary diagnostic 
manuals, the positive symptoms of schizotypal personality 
disorder were included in the ultra high-risk (UHR) criteria 
20 years ago, and nowadays are broadly employed in clini-
cal early detection of psychosis. The schizotypy construct, 
now dissociated from strict familial risk, also informed 
research on the liability to develop any psychotic disorder, 
and in particular schizophrenia-spectrum disorders, even 
outside clinical settings. Against the historical background 
of schizotypy it is surprising that evidence from longitu-
dinal studies linking schizotypy, UHR, and conversion to 
psychosis has only recently emerged; and it still remains 
unclear how schizotypy may be positioned in high-risk 
research. Following a comprehensive literature search, we 
review 18 prospective studies on 15 samples examining the 
evidence for a link between trait schizotypy and conver-
sion to psychosis in 4 different types of samples: general 
population, clinical risk samples according to UHR and/or 
basic symptom criteria, genetic (familial) risk, and clinical 
samples at-risk for a nonpsychotic schizophrenia-spectrum 
diagnosis. These prospective studies underline the value 
of schizotypy in high-risk research, but also point to the 
lack of evidence needed to better define the position of the 
construct of schizotypy within a developmental psychopa-
thology perspective of emerging psychosis and schizophre-
nia-spectrum disorders.
Key words:  schizophrenia/prodrome/adolescence/ 
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Introduction
Schizophrenia and other psychoses continue to be a sig-
nificant cause of disability-adjusted life years (DALYs). 
Moreover, despite the fact that only a small proportion 
of cases emerge during childhood and early adolescence,1 
they belong to the 10 main causes for DALYs already 
in 10–14-year-old boys.2 The full-blown clinical picture 
typically emerges during late adolescence and young 
adulthood. Increasingly conceptualized as a neurode-
velopmental “brain disorder,” psychoses represent the 
third most costly brain vulnerability in Europe.3 Thus, 
for the last 2 decades, increasing efforts have been put 
into developing early detection methods and preventive 
interventions before the development of a first episode 
of psychosis.4
Historically, the inherently developmental nature of 
psychosis has already been suggested in the definitions 
put forward by pioneers such as Emil Kreapelin and 
Eugen Bleuler who described latent forms of schizophre-
nia in relatives of schizophrenia patients.5,6 Rado7 and 
Meehl8 took up such observations in their development 
of a construct that they named schizotypy as a short-
hand expression for the psychodynamic expression of the 
genetic vulnerability to develop schizophrenia. Taking 
on a dimensional perspective, these observations and 
theories suggested a spectrum of  schizophrenic disorders, 
which, in some extreme cases and/or under unfavorable 
conditions, unfold into a clinically significant illness. In 
other words, efforts were taken to chart the developmen-
tal trajectories to illness hoping to perhaps deviate these 
trajectories onto less pathogenic paths at an early stage. 
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Today, this dimensional nature of schizophrenia-spec-
trum disorders is explicitly formulated in developmental 
terms, most notably by the dominant “neurodevelopmen-
tal” hypothesis.9
Surprisingly perhaps from this historical perspective, 
schizotypy research, with some notable exceptions,10–12 has 
devoted little attention to examining developmental tra-
jectories. Nevertheless, research on the clinical high risk 
(CHR) and emergence of psychotic disorders, including 
the “ultra-high risk” (UHR) approach13 in help-seeking 
samples and the psychometric approach to “Psychotic-
Like Experiences” (PLEs)14 in the general population, 
clearly relate to schizotypy. In fact, assessment instru-
ments developed in these approaches, and particularly 
those developed to assess UHR criteria, include phe-
nomena typically assessed as traits in schizotypy, in par-
ticular positive symptoms of Diagnostic and Statistical 
Manual of Mental Disorders (DSM) schizotypal person-
ality disorder such as unusual thought contents or magi-
cal thinking.15 The appointed trait-state characteristic 
of similar phenomena is the most important difference 
between UHR and schizotypy assessments as the for-
mer, particularly in its American operationalization by 
the “Structured Interview of Psychosis-Risk Syndromes, 
SIPS”16 a(table 1), requires a state characteristic and there-
fore necessitates to fulfill an “onset/worsening” require-
ment.15 Therefore cases where subclinical psychotic or 
schizotypal manifestations have “trait” character (stabil-
ity during the past) are excluded from the symptomatic 
UHR criteria. This “state” requirement is also inherent 
to the Attenuated Psychosis Syndrome17 newly included 
as a self-contained disorder in the research section of 
DSM-5.18
For these close phenomenological links between trait-
schizotypy and state-CHR, the current review critically 
assesses the value of the schizotypy construct for the 
prediction of psychosis in different population segments: 
the general population, genetic high risk samples, non-
psychotic patient samples with schizophrenia-spectrum 
disorder, and nonpsychotic patient samples meeting cur-
rent CHR criteria.
State of the Art in Early Detection of Clinical High-
Risk States of Psychosis
Psychoses are etiologically heterogeneous disorders, asso-
ciated to a variety of known risk factors. These include 
genetic factors that are among the strongest risk factors 
but still lack sufficient explanatory power for the emer-
gence of psychosis.19 Psychotic disorders are generally 
preceded by a prodromal phase of several years on aver-
age20 that might already lead to help seeking for mental 
problems.21 CHR research has therefore favored an indi-
cated prevention approach on symptomatic individu-
als experiencing the first signs of the emerging disorder, 
rather than a selective or universal prevention approach, 
focusing on symptom-free individuals with specific risk 
factors or on general population samples.22 With this 
focus on help-seeking clinical samples, early detection 
research clearly differs from the main focus of schizotypy 
research, ie on (genetic) risk samples or general popula-
tion samples.
From the perspective of  indicated prevention of  psy-
choses, 2 main concepts are usually applied when identi-
fying individuals in an CHR state:4 the UHR criteria that 
focus on detecting an imminent risk of  psychosis23 and 
the basic symptom criteria that focus on the detection of 
the earliest possible specific symptom.24 The 2 partially 
overlapping basic symptom criteria, “cognitive-percep-
tive basic symptoms” (COPER) and “cognitive distur-
bances” (COGDIS), include subtle self-experienced 
disturbances in thought, speech, and visual and acous-
tic perception processes. These are often not observable 
to others and are self-reported as phenomenologically 
different from mental states considered the “normal” 
premorbid self. As such, basic symptoms are clearly 
distinguishable from subtle disturbances described as 
traits in those at genetic high-risk25,26 and also from the 
observable odd speech and the unusual perceptual expe-
riences as described in schizotypy. Irrespective of  differ-
ences in their assessment, UHR criteria generally allow 
the identification of  3 subgroups of  CHR patients:15 (1) 
attenuated positive psychotic symptoms (APS), (2) brief  
limited intermittent psychotic symptoms below DSM-
IV’s duration criteria for a brief  psychotic episode,27 and 
(3) genetic risk, ie, familial risk or patient with schizo-
typal personality disorder (SPD), plus recent signifi-
cant functional decline. Patients with APS consistently 
account for the majority of  UHR patients.17 APS were 
modeled both on “psychotic-like experiences” defined by 
Chapman and Chapman28 as delusional and hallucina-
tory phenomena in that some insight is still maintained, 
and on the 5 positive DSM-III-R prodromal symptoms 
of  schizophrenia29 that are phenomenologically equal 
to the positive symptoms in the definitions of  the clini-
cal manifestation of  schizotypy, ie, DSM-IV’s SPD and 
ICD-10’s schizotypal disorder (SD)30 (table  1). Thus 
the main differences between the APS UHR criterion 
in its definition by the SIPS,16 SPD, SD, and the recent 
Attenuated Psychosis Syndrome, are (1) the inclusion of 
additional, mainly negative and disorganized symptoms 
in the criteria for SPD and SD; (2) the number of  symp-
toms required; and (3) the onset and frequency criteria 
and, related to these, the differential emphasis put on the 
state and trait character of  defining symptoms (table 1).
Irrespective of  the applied CHR criteria, the conver-
sion rate in CHR samples to first-episode psychosis, 
mainly of  the schizophrenia spectrum, was estimated 
to range from 18% at 6  months, 22% at 1  year, 29% 
at 2  years, to reach 36% at 3  years;4 as such, it shows 
a several 100-fold increase compared to the 0.035% 
12-month incidence of  psychosis in the community31 
S398
M. Debbané et al
Table 1. Comparison of the Attenuated Psychotic Symptoms (APS) UHR Criterion According to the “Structured Interview of 
Psychosis-Risk Syndromes” (SIPS)16 With the Diagnostic Criteria of SPD, Schizotypal Disorder, and Attenuated Psychosis Syndrome
APS Psychosis-Risk 
Criterion (SIPS 5.0) 
Schizotypal Personality Disorder 
(SPD) (DSM-IV-TR: 301.22)
Schizotypal Disorder (SD)  
(ICD-10: F21.0)
Attenuated Psychosis 
Syndrome (DSM-5, 
Section III)
Number of symptoms 
required: one or more SIPS 
item P1–P5 with a score of 
3–5 (see below)
Number of symptoms required: 5 
or more of the criteria-relevant 
symptoms detailed below
Number of symptoms required: 4 
or more of the criteria-relevant 
symptoms detailed below
Number of symptoms 
required: one or more 
of the criteria-relevant 
symptoms detailed 
below 
Onset: first appearance 
within the past year or 
current rating one or 
more scale points higher 
compared to 12 mo ago
Onset: symptoms form an enduring 
pattern of long duration and its 
onset can be traced back at least to 
adolescence or early adulthood 
Onset: symptoms must have 
manifested over a period of  
at least 2 y
Onset: first appearance 
within the past year 
or current rating one 
or more scale points 
higher compared to 12 
mo ago
Frequency: symptoms have 
occurred at an average 
frequency of at least once 
per week in the past month
Frequency: pattern is stable, 
inflexible, and pervasive across a 
broad range of personal and social 
situations 
Frequency: symptoms must have 
manifested over this period either 
continuously or repeatedly
Frequency: symptoms 
have occurred at an 
average frequency of at 
least once per week in 
the past month
Disability: the enduring pattern 
leads to clinically significant 
distress or impairment in social, 
occupational, or other important 
areas of functioning
Disability: symptom(s) 
is sufficiently 
distressing or disabling 
to the individual 
to warrant clinical 
attention
Exclusion: symptom(s) 
is not due to the direct 
physiological effects of 
a substance or a general 
medical condition; and not 
better explained by another 
DSM-5 diagnosis and has 
never been severe enough to 
meet diagnostic criteria for a 
psychotic disorder
Exclusion: not due to the direct 
physiological effects of a substance 
or a general medical condition; 
does not occur exclusively during 
the course of Schizophrenia, a 
Mood Disorder With Psychotic 
Features, another Psychotic 
Disorder, or a Pervasive 
Developmental Disorder
Exclusion: The subject must never 
have met the criteria for any 
disorder in F20 (Schizophrenia)
Exclusion: symptom(s) 
is not due to the 
direct physiological 
effects of a substance 
or a general medical 
condition; and not 
better explained 
by another DSM-5 
diagnosis and has never 
been severe enough to 
meet diagnostic criteria 
for a psychotic disorder
Criteria-relevant symptoms
 P1 Unusual Thought 
Content/delusional Ideas 
(includes odd beliefs, 
magical thinking, and 
delusions not held with 
absolute conviction)
Odd beliefs or magical thinking 
that influences behavior and is 
inconsistent with subcultural 
norms (eg superstitiousness, 
belief  in clairvoyance, telepathy, 
or “sixth sense”; in children and 
adolescents, bizarre fantasies 
or preoccupations); ideas of 
reference—nonparanoid
Odd beliefs or magical thinking 
influencing behavior and 
inconsistent with subcultural norms
Delusion in an 
attenuated form
 P3 grandiose ideas
 P2 suspiciousness/ 
persecutory ideas
Suspiciousness or 
paranoid ideation; ideas of 
reference—paranoid
Suspiciousness or paranoid ideas
 P4 Perceptual 
abnormalities/hallucinations 
(derealization is part of P1, 
depersonalization is part 
of one negative symptoms 
item, N4)
Unusual perceptual experiences, 
including bodily illusions
Unusual perceptual experiences 
including somatosensory (bodily) or 
other illusions, depersonalization, or 
derealization
Hallucination in an 
attenuated form
 P5 disorganized 
communication
Odd thinking and speech (eg vague, 
circumstantial, metaphorical,  
over-elaborate, or stereotyped)
Vague, circumstantial, metaphorical, 
over-elaborate, or often stereotyped 
thinking, manifested by odd speech 
or in other ways, without gross 
incoherence
Disorganized speech in 
an attenuated form
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and significantly higher conversion rates than CHR-
negative help-seekers in specialized early detection ser-
vices.32 More recent studies combining UHR and basic 
symptom criteria reported a conversion rate of  patients 
meeting both basic symptom (especially COGDIS) and 
UHR criteria (especially APS) that was roughly 3 times 
higher than that of  patients meeting one but not the other 
criterion.33,34 However, real long-term conversion data is 
only slowly accumulating, and from one UHR sample 
(N  =  311; mean follow-up: 7.5 ± 3.2  years), an overall 
conversion rate of  transition was estimated to reach 
35% over a 10-year period,35 while from one basic symp-
tom sample (N = 160; mean follow-up: 9.6 ± 7.6 years), 
an overall conversion rate across the follow-up of  65% 
for COPER and 79% for COGDIS was reported.36,37 
Thus, in order to improve prediction and reduce the rate 
of  nonconverters, the search for additional predictors 
continues on all possible levels—from psychopathol-
ogy to genetic factors including schizotypy as a possible 
expression of  a genetic liability.4
Yet, nonconverters of CHR samples do not generally 
have a favorable outcome: a recent study showed that in 
34%–82% nonconverters, UHR symptoms persisted over 
1–3 years;13 40% had poor social or role outcomes after 
3 years;38 and 75% were diagnosed with anxiety, affective 
or substance use disorder after 1 year.39 Thus, it was con-
cluded that APS in particular predict more severe mental 
conditions and not only psychoses.38,39 Along this line of 
argument, an Attenuated Psychosis Syndrome (table  1) 
was tentatively included in DSM-518 as a self-contained 
disorder with treatment focus on current symptoms but 
not a risk syndrome with treatment focus on prevention 
of assumed future psychotic symptoms.40
Thus, while current CHR criteria already provide good 
starting-points to detect emerging psychotic disorders, 
the predictive and discriminative power to parse noncon-
verters from converters should be further improved to 
identify a target group for specific preventive interven-
tions.4 To date, it is not yet clear how the trait construct 
of schizotypy could complement CHR state assessment 
beyond the minor role it currently plays as a risk fac-
tor in the UHR GRDF criterion. Further, it remains to 
be shown how schizotypy could be conceptualized with 
regards to emerging schizophrenia-spectrum disorders. 
Critically, the relationship between schizotypy and clini-
cal outcome needs to be evaluated if  researchers are to 
refer to schizotypy as a potent object of clinical research. 
In order to evaluate the link between schizotypy and clin-
ical outcome, in particular psychosis, the following sec-
tion provides an overview of longitudinal studies on the 
role of schizotypy as a potential predictor of psychotic 
disorders that might also act as an amplifier in CHR sam-
ples (figure 1).
Schizotypy in Emerging Psychosis
In the following selection of  studies, the potential links 
between the multidimensional schizotypy construct and 
emerging psychosis as defined by positive symptoms 
are examined. In our conceptualization of  schizotypy, 
we followed the broad description provided by Nelson 
and colleagues in their recent review.41 Despite some 
disagreement regarding the underlying factor structure 
of  schizotypy, they concluded that the prevailing cur-
rent understanding of  schizotypy is that it is comprised 
of  3 factors, which broadly correspond to the positive, 
APS Psychosis-Risk 
Criterion (SIPS 5.0) 
Schizotypal Personality Disorder 
(SPD) (DSM-IV-TR: 301.22)
Schizotypal Disorder (SD)  
(ICD-10: F21.0)
Attenuated Psychosis 
Syndrome (DSM-5, 
Section III)
Additional symptoms:
inappropriate or constricted affect;
behavior or appearance that is odd, 
eccentric, or peculiar;
lack of close friends or confidants 
other than first-degree relatives;
excessive social anxiety that does 
not diminish with familiarity 
and tends to be associated with 
paranoid fears rather than negative 
judgments about self
Additional symptoms:
inappropriate or constricted affect, 
subject appears cold and aloof; 
behavior or appearance which is 
odd, eccentric, or peculiar;
poor rapport with others and a 
tendency to social withdrawal; 
ruminations without inner 
resistance, often with 
dysmorphophobic, sexual, or 
aggressive contents;
occasional transient quasi-psychotic 
episodes with intense illusions, 
auditory, or other hallucinations 
and delusion–like ideas, usually 
occurring without external 
provocation
Note: DSM, Diagnostic and Statistical Manual of Mental Disorders.
Table 1. Continued
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negative and disorganized dimensions of  schizophrenia 
(figure 1). The first “positive” factor is the “cognitive-
perceptual factor,” which includes magical thinking, 
unusual perceptual experiences, ideas of  reference 
and paranoia. Another “disorganized factor” includes 
odd behavior and odd speech. The third is the “inter-
personal factor,” which resembles the negative dimen-
sion of  schizophrenia and includes constricted affect, 
social anxiety, lack of  close personal relationships, 
and suspiciousness. Consequently, we did not include 
studies that only assessed the dimensions of  hypoma-
nia or impulsiveness/nonconformity (or Eysenck’s psy-
choticism scale that had informed the initial definition 
of  impulsiveness/nonconformity) that are currently 
related to and primarily examined in emerging affective 
disorders.42,43
Literature Search
About 219 potential studies of  interest were retrieved 
from PubMed for the search: schizotypy AND (psy-
chosis OR schizophrenia) NOT (neurocognitive OR 
psychological OR genetic OR imaging OR EEG OR 
psychometric); these were complimented by a subse-
quent screening of  the qualifying articles’ references. For 
the selection of  qualifying articles, we employed the fol-
lowing criteria:
1. Study had a prospective longitudinal design with a 
minimum of 2 assessment points.
2. Outcome assessments included a clinical measure of 
psychosis (either a categorical diagnosis or a dimen-
sional scale for the assessment of frank positive psy-
chotic symptoms).
3. Baseline assessments included a measure of at least 2 
dimensions of the triad of schizotypy: positive schizo-
typy (cognitive-perceptual phenomena), negative 
schizotypy (interpersonal/affective phenomena) and/
or disorganization schizotypy (cognitive-behavioral 
phenomena). In effect, the third criterion excluded a 
number of epidemiological studies measuring PLEs 
that heavily rely on the positive dimensions of subclin-
ical expression.
4. Longitudinal analyses assessed the relationship 
between the baseline schizotypy assessment(s) and the 
clinical outcome measure(s).
There was no restriction related to sample characteris-
tics, and 4 types of samples were identified: general popu-
lation samples, CHR samples (as defined in the previous 
section), genetic risk samples (familial risk; first- and 
second-degree relatives), and clinical samples with a non-
psychotic schizophrenia-spectrum disorder, ie, schizo-
typal or schizoid personality disorders. A  total of 18 
studies (15 independent longitudinal samples) qualified 
for our review. A summary of their main characteristics 
and findings is provided in table 2.
General Population Samples
Four independent samples encompassing a total of 7282 
participants were included in studies spanning from 5 to 
50 year study intervals (table 2). All studies suggested that 
ratings of schizotypal dimensions significantly relate to 
later development of either psychotic disorders or schizo-
phrenia spectrum disorders.44–49 More specifically, they 
suggest that the positive dimension is mainly associated 
to the later emergence of psychotic disorders, while the 
negative dimension (especially anhedonia) is rather selec-
tively associated with the emergence of nonpsychotic 
schizophrenic-spectrum disorders. Information on the 
disorganization dimension was completely missing as 
none of these general population studies had assessed 
this dimension (table 2).
These results may inform large-scale screening and 
primary prevention strategies in the general popula-
tion. Further, they suggest that in psychosis high-risk 
research schizotypy should not be reduced to its posi-
tive dimension but assessed multidimensionally (both 
Fig. 1. Model of the assumed relationship and interactions 
between dimensions of schizotypy, clinical expressions of 
schizotypy, symptomatic CHR criteria, and overt psychosis. 
In line with Rado’s and Meehl’s description, this dimensional 
model assumes a distribution of schizotypal characteristics in 
the general population from absence via clinically significant 
expressions in terms of schizotypal (personality) disorder (SPD) 
to the most extreme, ie, psychotic expression, with increasing 
severity of schizotypy being associated with higher levels of 
distress and/or functional impairment. Attenuated psychotic 
symptoms (APS) might appear at as a clinical manifestation or 
as an exacerbation of the underlying schizotypy, in particular 
of features of the cognitive-perceptual and, though to a lesser 
degree, the disorganization dimension. The occurrence of APS 
might be triggered by aberrations in information processing at 
neurobiological level that are perceived and expressed as basic 
symptoms, in particular of cognitive-perceptive basic symptoms 
and cognitive disturbances. Neurobiological aberrations have been 
consistently described in multitude for patients with psychosis, 
while physiological correlates of schizotypy in terms of a trait or 
biomarker are yet to be discovered.
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Table 2. Outline of the Reviewed Longitudinal Studies Linking Schizotypy to Clinical Outcome in 4 Different Types of Studies: General 
Population Studies, Clinical Studies of ARMS Samples, Genetic Risk Studies, and Clinical Studies of Patients Diagnosed With SPD, 
SD, or Schizoid PD
Study Sample Age (n) Study Interval Schizotypy Assessment Conversion to Psychosis 
General population studies
 Kwapil et al44 General pop. 
(College 
students)
Mean age 19.3 y 
(n = 534)
10 y SADS-L; Wisconsin 
manual for assessing 
psychotic–like experiences; 
positive and negative 
schizotypy
Positive and negative 
schizotypy predict 
Schizophrenia spectrum 
disorders (n = 5); only 
positive schizotypy predicts 
psychotic disorders (n = 14)
 Kwapil45 Same sample as Kwapil et al44 Same assessment as  
Kwapil et al44
24% of high scorers on the 
Revised Social Anhedonia 
Scale develop Schizophrenia 
spectrum by age 30
 Chapman et al46 Same sample as Kwapil et al44 Same assessment as  
Kwapil et al44
5% of high scorers on the 
Perceptual Aberration or 
Magical Ideation Scales 
developed Schizophrenia over 
10 y; 40% if identified with 
criteria combining Magical 
Ideation and the Revised 
Social Anhedonia Scale
 Miettunen et al47 General pop 
(Northern 
Finland 1966 
Birth cohort)
31 y (n = 4871; 
assessed in 1997; 
excluding n = 55 
with previous 
psychotic 
diagnosis)
11 y 
(hospitalizations 
between 1998 | 
and 2008)
Perceptual Aberration, 
Physical and Social 
Anhedonia scales 
(Chapman Scales); 
Hypomanic Personality 
scale; Bipolar II scale; 
Schizoidia Scale; and 
Temperament and 
Character Inventory
Social Anhedonia and the 
Hypomanic Personality 
scale showed consistently 
higher scores in persons 
developing any psychotic 
disorder after the age of 
31 (n = 30) than those 
not developing a mental 
disorder (n = 4734). Physical 
anhedonia was significantly 
lower in those developing 
psychosis than in those 
developing another mental 
disorder (n = 107)
 Bogren et al48 General pop. 0–92 y, median 
age 33 y 
(n = 1797)
40–50 y Semistructured clinical 
interview of schizoid and 
schizophrenia-related 
personality features
“Paranoid-schizotypal” 
rating as one of 4 predictors 
of psychosis (n = 61), but 
not schizophrenia (n = 17).
 Gooding et al49 General pop. 
(College 
students)
Mean age 23.8 y 
(n = 135)
5 y Same assessment as  
Kwapil et al44
PerMag risk group double % 
of schizophrenia spectrum 
disorders (all SPD) than 
controls (n =8)
Studies in clinical samples with clinical high risk (CHR) state of psychosis
 Salokangas et al50 CHR sample; 
UHR & 
COGDIS
16–35 y, mean age 
22.4 y (n = 245)
18 mo Schizotypal Personality 
Questionnaire (SPQ)
Subscales “Ideas of reference” 
and “no close friends” were 
predictors of conversion to 
psychosis (n = 39)
 Ruhrmann et al33 same CHR sample as in Salokangas et al. 2013 SIPS-defined SPD 
(presence of only at least 1 
y required)
SIPS-defined SPD was one 
of 6 predictors of psychosis 
included in the predictor 
model
  Schultze-Lutter 
et al51
CHR sample; 
UHR and 
COPER
16–38 y (n = 100) 
converters 
(n= 50) and 
risk-, age- and 
gender-matched 
nonconverters 
(n = 50)
1–5.5 y (46 ± 17 
mo)
Selbstbeurteilung nach der 
Aachener Merkmalsliste 
für Persönlichhkeits- 
störungen (SAMPS);  
(Self-assessment according 
tot he Aachen symptom 
list for personality 
disorders)
Only schizoid subscale 
score was a significant 
though weak predictor of 
conversion; in particular 
items “lack of close friends 
or confidants other than 
first-degree relatives” and 
“emotional detachment 
observed by others”
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the positive and negative dimensions) to enable a dif-
ferential risk assessment for psychotic disorders on the 
one hand, and nonpsychotic personality-related disor-
ders on the other.
Studies in Clinical High-Risk Samples
We identified 5 CHR studies on 4 samples with a total 
of  369 patients and follow-ups ranging from 18 months 
to 5.5  years (table  2).33,36,50–52 Irrespective of  whether 
Study Sample Age (n) Study Interval Schizotypy Assessment Conversion to Psychosis 
 Mason et al52 CHR sample; 
UHR
13–28 y, mean age 
17.3 y (n = 74)
1–2 y 
(26 ± 9 months)
SPD subscale of the 
International Personality 
Disorder Examination 
(IPDE) and Assessment 
of Prodromal and 
Schizotypal Symptoms 
(APSS)
Only schizotypal personality 
characteristics led to a 
significant increase in 
predictive power of UHR 
criteria for conversion to 
psychosis (n = 37), but 
considered as of low clinical 
utility
  Klosterkötter 
et al36
Clinical sample 
suspected 
to develop 
psychosis
Mean age 29.3 y 
(n = 160)
≥5 y (9.6 ± 7.8 y) Clinical diagnosis of 
personality disorders 
(DSM-III-R criteria)
Irrespective of the presence 
of CHR criteria, only SPD 
of all baseline diagnoses was 
significantly related to the 
subsequent development of 
schizophrenia (n = 79) in the 
total sample
Genetic risk studies
 Shah et al53 Genetic-high risk 8–25 y, mean age 
15.9 y (n = 96)
2.4 ± 1 y Perceptual Aberration, 
Magical Ideation and 
Social Anhedonia scales 
(Chapman Scales)
The 3 scales were significant 
predictors within the 
multivariate risk algorithm 
for psychosis (n = 12)
 Johnstone et al54 Genetic high 
risk and “well” 
controls
16–25 y, mean age 
21.2 y (n = 173)
5 y Structural Interview for 
Schizotypy (SIS) and Rust 
Inventory of Schizotypal 
Cognitions (RISC)
SIS total score and subscales 
“Oddness” and “Social 
withdrawal factor” as well as 
RISC total score constituted 
4 of 5 predictors of 
conversion to schizophrenia 
(n = 20)
 Carter et al55 Genetic high risk 9–22 y, mean age 
15.1 y (n = 207)
25 y Minnesota Multiphasic 
Personality Inventory 
(MMPI)
Wiggin’s Psychoticism scale 
of MMPI as a predictor of 
schizophrenia (n = 31)
  Erlenmeyer- 
Kimling et al56
Genetic high risk 
and clinical and 
normal controls
7–12 y, mean age 
9.5 y (n = 161)
9–11 y Physical Anhedonia Scale 
(PhyA)
Physical anhedonia as a 
direct precursor of psychosis 
(n = 13) in females but not 
males
Clinical studies of patients diagnosed with SPD, SD or schizoid PD
 Nordentoft et al57 Patients with SD 18–45 y mean age 
24.9 y (n = 79)
2 y ICD-10 diagnosis Rate of conversion to 
psychotic disorder: 25% in 
specialized treatment group 
and 48% in standard care 
group (total diagnosed with 
psychotic disorder = 23)
 Wolff  et al58 Children 
clinically 
diagnosed as 
“schizoid”
4.3–14.6 y, mean 
age at first referral 
9.83 y (n = 32)
≥20 y Clinical semistructured 
interview
Three quarters if  clinical 
sample developed SPD 
during adults, while 6.25% 
(n = 2) were diagnosed with 
a schizophrenia-spectrum 
psychotic disorder
  Fenton and 
McGlashan59
Inpatients; 
DSM- 
III borderline or 
SPD
Mean age 29 y 
(n = 105)
Mean 15 y after 
discharge
DSM-III-SPD “magical thinking,” “social 
isolation,” suspiciousness/ 
paranoid ideation” as 
predictors of psychosis 
(n = 18)
Note: DSM, Diagnostic and Statistical Manual of Mental Disorders; SD, schizotypal disorder according to ICD; SPD, schizotypal 
personality disorder (PD) according to DSM.
Table 2. Continued
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self-report questionnaires or clinical semistructured 
interviews were used in the assessment of  schizotypy, 
there was some though not consistent indication that 
schizotypal dimensions might play a role in the conver-
sion to psychosis in patients already identified at CHR 
prior to and independently from schizotypy assess-
ment. One of  the key questions with regard to this par-
ticular clinical population is whether the addition of  an 
assessment of  schizotypy can significantly increase the 
predictive power of  already-existing CHR criteria. In 
addressing this question, Mason et al.52 argued that, from 
a statistical point of  view, schizotypy might increase the 
predictive power of  UHR criteria; however, from a clini-
cal point of  view, this contribution might be of  limited 
actual value. Indeed, comparing the schizotypy scores 
between converters and nonconverters in this study did 
not yield a critical difference that could be meaningfully 
implemented in clinical practice (only a 2 scale-point 
increase in converters, representing a measure difference 
below 2 standard deviations). Furthermore, the study 
did not clearly distinguish trait manifestations (long 
lasting—2 to 5 years) from state manifestations (present 
within the past month), a distinction necessary to estab-
lish the role of  schizotypy in the psychotic developmen-
tal process.
Overall, CHR studies suggest that, contrary to the 
findings in general population samples, the positive 
dimension of  schizotypy was of  little, if  any value in 
terms of  increasing the psychosis-predictive accuracy 
in samples already considered to be prone to psychosis 
for UHR and/or basic symptom criteria. Rather, when 
schizotypy was differentially assessed, the interpersonal, 
negative dimension seemed to explain additional vari-
ance and to assist the detection of  converters to psycho-
sis. With regard to the large phenomenological overlap 
between UHR criteria, in particular APS, and the posi-
tive and disorganized dimensions of  schizotypy but 
not with its negative dimension (table 1), this finding is 
hardly surprising. However, all but one study on CHR 
patients33 had rather short follow-ups that might not 
have been sufficient to detect an insidious development 
of  psychosis in patients with more pronounced schizo-
typy (figure 1).
As early detection is moving increasingly into younger 
age groups, the need to distinguish between develop-
ing but stable schizotypal traits or SPD, and develop-
ing but novel psychotic symptoms or APS in children 
and adolescents becomes more imperative.1,60 Further, 
CHR patients with high scores on schizotypy measures 
might in general require an adaptation in early inter-
vention techniques; these should not only address posi-
tive symptoms of  schizotypy or APS (such as unusual 
thought contents) as a—possibly neurobiological 
based—deviation from premorbid information process-
ing but also the general aberrant information process-
ing style and way to experience and interpret the world 
(figure 1). Moreover, standard care interventions might 
not be optimally suited to address the needs of  patients 
with pronounced negative features of  the interpersonal 
dimension not captured by CHR criteria (figure  1) 
whose personality traits and ensuing social environ-
ment are characterized by enduring social withdrawal 
and poverty of  interpersonal relationships. Clinical 
research is only starting to address these questions.61,62 
Furthermore, from a neuropharmacological point of 
view, symptom profiles with more pronounced negative/
interpersonal and disorganization dimensions are still 
not adequately addressed by current treatment guide-
lines of  schizophrenia.63 Thus, current evidence seems 
to be in favor of  the inclusion of  a multidimensional 
assessment of  schizotypy in CHR studies, in particular 
as current and future clinical research move into the 
evaluation of  early intervention strategies.64
Genetic High-Risk Samples
The 4 identified studies on samples at genetic risk for 
psychosis included a total of  637 offsprings (first- or 
second-degree relatives) of  patients diagnosed with 
schizophrenia, and covered follow-ups between 8 and 
25  years.53–56 Similar to general population studies, 
schizotypy dimensions were found to be significantly 
associated with the later emergence of  psychotic disor-
ders in genetic high-risk samples. However, no clear pat-
tern of  associations between schizotypal dimension and 
either psychotic or schizophrenic-spectrum disorders 
emerged. Yet, substantially different assessment methods 
were employed over the 20-year span covered by these 
studies (1993 and 2012)  that may have contributed to 
the heterogeneity of  findings. The most recent study by 
Shah and colleagues,53 underscored the pre-eminence of 
schizotypy amongst a variety of  predictive risk factors 
from etiological (degree of  relatedness to family mem-
ber with schizophrenia: genetic risk), to environmental 
(cannabis use, obstetric complications, welfare), and 
cognitive (IQ, perseveration, verbal fluency) assessments. 
In a multivariate structural equation model, only base-
line ratings on the Chapman scales (Magical Ideation, 
Perceptual Aberration, and Social Anhedonia Scales) 
were directly and positively related to conversion to psy-
chotic disorders. Interestingly, many risk factors included 
in this analysis represent distal factors that might also 
be developmentally significant to schizotypy, as most of 
them significantly correlate with adolescent expression 
of  trait schizotypy.65 For this reason, it has been argued 
that schizotypal traits during adolescence could repre-
sent a developmental link between early risk factors and 
later development of  psychotic disorders (Debbané & 
Barrantes-Vidal, this issue). However, more longitudinal 
research on the complex relationships between early and 
intermediate risk indicators for psychosis is needed to 
examine this assumption.
S404
M. Debbané et al
Clinical Studies of Patients Diagnosed With SPD, SD, 
or Schizoid PD
The 3 studies that examined the development of psy-
chosis in patients characterized by a clinically relevant 
expression of schizotypy (ie, SPD, schizoid PD, or SD) 
but with no information on psychometric schizotypy and 
thus on the different dimensions involved 376 patients 
followed for 2–20 years.57,58,66 Ever since introducing the 
diagnosis of SPD into the DSM, the actual rate of con-
version from SPD to schizophrenia-spectrum psychosis 
has been an object of speculation.67 In a recent study on 
adult in- and outpatients diagnosed with SPD, the con-
version rates to a psychotic disorder varied between 25% 
and 48%.57 Suspected SPD in children however seldom 
led to the later emergence of a schizophrenic-spectrum 
psychotic disorder (only 6.25%), although SPD will ensue 
in 3 quarters of the cases.68 Thus, an association between 
SPD and psychosis is clearly indicated yet its details 
necessitate further validation. Future studies of this clini-
cal group should therefore provide dimensional scores of 
schizotypy to clarify the possible patterns of associations 
between SPD and emerging psychotic disorders.
General Results and Limitations
Taken together, the above studies of schizotypy in general 
population, CHR, genetic risk and non-psychotic schizo-
phrenia-spectrum disorder samples suggested a longitu-
dinal associations between measurements of schizotypy 
and later development of a psychotic disorder. The litera-
ture search, however, was likely biased towards positive 
results, because studies that had included schizotypy as 
just one of many potential predictors but failed to find a 
significant schizotypy–related result (such as the NAPLS 
study)69 unlikely mention schizotypy in title, key words, or 
abstract. Consequently, these negative findings would be 
undetected in our literature search.69 Furthermore, while 
associations between schizotypy and schizophrenia-spec-
trum disorders were reported in some instances,44,45 they 
necessitate further replication from independent samples 
in studies specifically designed to address this topic. 
Importantly, most studies lack a consistent evaluation of 
the disorganization dimension of schizotypy, a dimension 
associated with the developmental process of schizotypy 
during adolescence,70,71 and with known endophenotypes 
of schizophrenia.72
Schizotypy in the Field of High-Risk for Psychosis 
Research
Longitudinal studies assessing the relationship between 
schizotypy and clinical outcome pointed towards the con-
struct of schizotypy—in clinical as well as psychometric 
terms—as a significant though weak predictor of psycho-
sis. Importantly, the results indicated the importance of 
the multidimensionality of the schizotypy construct, and 
the value of assessing at least both the positive (cognitive-
perceptual) and negative (affective-interpersonal) dimen-
sions of schizotypy. As the third, ie, the disorganized 
dimension was unconsidered by studies, their psychosis-
predictive value remains to be investigated. Several other 
points, however, require further examination. Firstly, it is 
not clear whether dimensions of schizotypy preferentially 
predict the emergence of psychotic disorders in general, 
or more specifically schizophrenia-spectrum psychotic 
disorders. Studies do not always distinguish between dif-
ferent subclassifications of psychotic and schizophrenia-
spectrum psychotic disorders, which would be necessary 
to gain better insight in this issue. Secondly, gender dif-
ferences that are frequent in personality disorders and 
dimensions73,74 have not been systematically investigated; 
only one study reported Physical Anhedonia as specifi-
cally related to risk in female participants.56 Thirdly, age-
related peculiarities in the assessment of schizotypy have 
not been studied. Yet, research on adolescents from the 
community suggested higher prevalence rates of, particu-
larly perception–related APS in younger adolescents,75 
and a similar age bias was observed in adolescent posi-
tive schizotypy.70 Such age-related characteristics may 
well lower the risk for psychosis by (attenuated) hallu-
cinations and/or unusual thought contents in young age 
groups. Fourthly, cultural or Zeitgeist influences on the 
assessment of schizotypy have not been addressed to 
date in cross-cultural or longitudinal studies but might 
explain differences in findings across countries or time. 
For example, comparison of prevalence rates in DSM-
SPD between German and North American high-risk 
and community samples consistently found 3- to 4-fold 
higher rates in American samples,47 and statements such 
as “the government refuses to tell the truth about UFOs” 
(item of the Magical Ideation scale relating to specula-
tions about area 51)  might not possess general or lose 
timeliness.
With regards to an early clinical detection of  psycho-
sis, 3 of  4 studies examining the additive value of  assess-
ing schizotypy in CHR sample found merits in it.31,46,52 
Yet it was argued that while an assessment of  schizo-
typy increased predictive value statistically, it might fail 
to carry substantial clinical meaning in terms of  dis-
criminating non-converters and converters.52 Although 
further research is needed to confirm this appraisal, it 
appears that schizotypy may be more useful as a dis-
tal risk marker, and employed to select psychosis-prone 
persons early on to examine some of  the initial inter-
actions leading to CHR states and possibly psychosis. 
Indeed, in comparison to CHR state risk indicators, 
schizotypy measures might not be equally predictive of 
psychosis. However, beyond 3- to 5-year intervals, state 
markers may be traded for trait markers such as schizo-
typy, for which predictive value over intervals as lengthy 
as 25–50 years was reported. Further, schizotypy mea-
sures might be included as a lower risk predictor in 
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psychopathological risk stratification models and/or 
improve knowledge of  the pretest illness probability so 
important for an adequate evaluation of  the post-test 
illness probability, eg, after the assessment of  CHR 
criteria.76
To conclude, the concept of  schizotypy has already 
informed preventive research in psychoses to an impor-
tant degree, particularly with regard to the definition of 
the UHR criteria. Yet, while it seems to have the abil-
ity to detect psychosis-prone subjects from the commu-
nity, long-term prospective studies combining both trait 
and state markers, ie, including schizotypy-identified but 
otherwise mentally well persons and CHR patients, are 
still missing. As CHR patients must be assumed to rep-
resent already the more extreme end of  the schizotypy-
psychosis continuum, such studies would preferably be 
conducted in primary care settings or on large commu-
nity samples.
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